^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRCA1 mutation + BRCA2 mutation

    i
    Other names: BRCA2, BRCC2, FACD, FAD, FAD1, FANCD, FANCD1, Breast cancer 2, early onset, BRCA1, BRCC1, PPP1R53, RNF53, Breast cancer 1, early onset
    Entrez ID:
    672; 675
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... (NCT02484404)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/07/2024
    Initiation :
    06/29/2015
    Primary completion :
    12/30/2024
    Completion :
    12/30/2025
    EGFR • HER-2 • BRAF • ALK • PGR • BRCA1 • BRCA2
    |
    BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • ALK translocation • BRCA1 mutation + BRCA2 mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
    Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer (COMETABreast) (NCT03205761)
    Phase 2
    Spanish Breast Cancer Research Group
    Completed
    Last update posted :
    06/06/2024
    Initiation :
    10/23/2017
    Primary completion :
    12/15/2022
    Completion :
    12/15/2022
    HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • BRCA1 mutation + BRCA2 mutation • BRCA mutation • PGR expression • BRCA1 promoter methylation
    |
    Lynparza (olaparib)
    Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors (NCT04182516)
    Phase 1
    Nerviano Medical Sciences
    Active, not recruiting
    Last update posted :
    04/22/2024
    Initiation :
    11/25/2019
    Primary completion :
    03/31/2023
    Completion :
    12/30/2024
    HER-2 • BRCA1 • BRCA2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • BRCA1 mutation + BRCA2 mutation
    |
    NMS-293
    FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer (S1513) (NCT02890355)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    04/05/2024
    Initiation :
    09/01/2016
    Primary completion :
    05/01/2019
    Completion :
    03/05/2025
    BRCA1 • BRCA2 • HRD • CEACAM5
    |
    BRCA2 mutation • BRCA1 mutation • HRD • HRD + BRCA1 mutation • BRCA1 mutation + BRCA2 mutation
    |
    5-fluorouracil • irinotecan • veliparib (ABT-888) • leucovorin calcium • fluorouracil topical
    Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations (NCT00823654)
    Phase N/A
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    02/02/2024
    Initiation :
    01/01/2009
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    HER-2 • BRCA1 • BRCA2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 overexpression • BRCA1 mutation + BRCA2 mutation
    NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients (iRetroBC) (NCT06131424)
    Phase N/A
    AstraZeneca
    Not yet recruiting
    Last update posted :
    01/24/2024
    Initiation :
    03/04/2024
    Primary completion :
    09/30/2024
    Completion :
    09/30/2024
    HER-2 • ER • PIK3CA • BRCA1 • PTEN • ATM • AKT1
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • PIK3CA mutation • HER-2 expression • ATM mutation • PALB2 mutation • ESR1 mutation • BRCA1 mutation + BRCA2 mutation
    Clinical Significance of Germline BRCA Mutations (NCT00579488)
    Phase N/A
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    11/14/2023
    Initiation :
    07/01/1996
    Primary completion :
    07/01/2025
    Completion :
    07/01/2025
    BRCA1 • BRCA2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation
    of Androgen Receptor Expression in Breast Cancer With or Without BRCA Mutation (NCT05404334)
    Phase N/A
    Banaras Hindu University
    Recruiting
    Last update posted :
    06/06/2022
    Initiation :
    07/01/2021
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    BRCA1 • BRCA2 • AR • BRCA
    |
    BRCA2 mutation • BRCA1 mutation • AR expression • BRCA1 mutation + BRCA2 mutation • BRCA mutation
    Characterizing the Cross-sectional Approach to Investigate the Prevalence of Tissue BRCA1/2 Mutations in Newly Diagnosed Advanced Ovarian Cancer Patients (CHRISTELLE) (NCT04222465)
    Phase N/A
    AstraZeneca
    Completed
    Last update posted :
    10/26/2021
    Initiation :
    03/19/2020
    Primary completion :
    11/13/2020
    Completion :
    11/13/2020
    BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation
    Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer (NCT01623349)
    Phase 1
    Dana-Farber Cancer Institute
    Completed
    Last update posted :
    02/10/2021
    Initiation :
    09/01/2012
    Primary completion :
    05/01/2019
    Completion :
    12/01/2020
    BRCA1 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation
    |
    Lynparza (olaparib) • Piqray (alpelisib) • buparlisib (AN2025)
    Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region (PREDICT) (NCT03082976)
    Phase N/A
    AstraZeneca
    Completed
    Last update posted :
    07/16/2020
    Initiation :
    07/16/2017
    Primary completion :
    07/24/2019
    Completion :
    07/24/2019
    BRCA1 • BRCA2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation • BRCA mutation
    FLABRA: Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic Study (NCT02984423)
    Phase N/A
    AstraZeneca
    Completed
    Last update posted :
    07/10/2020
    Initiation :
    12/27/2016
    Primary completion :
    06/30/2019
    Completion :
    06/30/2019
    BRCA1 • BRCA2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation + BRCA2 mutation • BRCA mutation
    Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study (NCT02514499)
    Phase N/A
    Abramson Cancer Center of the University of Pen...
    Completed
    Last update posted :
    07/24/2019
    Initiation :
    07/01/2014
    Primary completion :
    10/01/2018
    Completion :
    10/01/2018
    BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation • BRCA1 negative
    Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer (NCT00588263)
    Phase N/A
    Memorial Sloan Kettering Cancer Center
    Withdrawn
    Last update posted :
    02/19/2018
    Initiation :
    07/01/2000
    Primary completion :
    07/01/2018
    Completion :
    07/01/2018
    BRCA1 • BRCA2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation